Lake Street raised the firm’s price target on iRadimed (IRMD) to $120 from $100 and keeps a Buy rating on the shares after “another beat” in Q4. The firm continues to believe the execution track record and profitability profile support a premium valuation and while guidance for 2026 was marginally ahead of expectations, it believes the company left room for upside as the 3870 launch progresses.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRMD: